TGTX logo

TGTX
TG Therapeutics Inc

21,489
Mkt Cap
$5.11B
Volume
1.84M
52W High
$46.48
52W Low
$25.28
PE Ratio
11.52
TGTX Fundamentals
Price
$31.98
Prev Close
$31.82
Open
$31.51
50D MA
$29.76
Beta
0.96
Avg. Volume
1.66M
EPS (Annual)
$2.77
P/B
7.66
Rev/Employee
$1.54M
$4,923.45
Loading...
Loading...
News
all
press releases
1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co.
Congress Asset Management Co. purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
TG Therapeutics Procures Additional $500 Mln Funding From Blue Owl Capital
(RTTNews) - TG Therapeutics, Inc. (TGTX), a commercial stage biopharmaceutical company, Thursday announced that it has obtained a new five-year, $750 million senior secured credit facility with funds...
Nasdaq News: Markets·8d ago
News Placeholder
Penn Capital Management Company LLC Grows Stock Position in TG Therapeutics, Inc. $TGTX
Penn Capital Management Company LLC boosted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 17.6% during the third quarter, according to the company in its most recent filing...
MarketBeat·9d ago
News Placeholder
TG Therapeutics (NASDAQ:TGTX) Shares Up 7.9% - Here's What Happened
TG Therapeutics (NASDAQ:TGTX) Trading 7.9% Higher - Time to Buy...
MarketBeat·9d ago
News Placeholder
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
Key PointsACT Capital Management added 268,875 shares of TG Therapeutics in the fourth quarter...
Nasdaq News: Markets·10d ago
News Placeholder
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·15d ago
News Placeholder
TG Therapeutics, Inc. $TGTX Stake Cut by Teachers Retirement System of The State of Kentucky
Teachers Retirement System of The State of Kentucky decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 47.5% in the 3rd quarter, according to the company in its...
MarketBeat·21d ago
News Placeholder
TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright
TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at HC Wainwright dropped their Q4 2026 earnings estimates for shares of TG Therapeutics in a research note issued to investors on...
MarketBeat·23d ago
News Placeholder
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·25d ago
News Placeholder
HC Wainwright Raises Earnings Estimates for TG Therapeutics
TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for TG Therapeutics in a research report issued to clients and...
MarketBeat·25d ago
<
1
2
...
>

Latest TGTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.